Privi Speciality Chemicals Limited has informed the Exchange about Transcript

Privi Speciality Chemicals reported strong FY26 results with revenue of Rs 2,583 crore (up 22% YoY), EBITDA of Rs 665 crore (up 40%), and PAT of Rs 328 crore (up 75%). EBITDA margins improved to 25.76% from 22.35% previously, driven by volume growth of 6.5%, 8% price increase, and improved product mix. The company expects to sustain 20%+ EBITDA margins going forward and targets 20% revenue growth in FY27. Capex expansion is on track with Phase 1 completing by June 2026 (capacity to 54,000 MT), and Phase 2 reaching 72,000 MT by 2028. The JV with Givaudan (PRIGIV) turned profitable in Q4 and expects revenue of Rs 130 crore in FY27 (vs Rs 55 crore in FY26). Management guided toward a long-term target of Rs 5,000 crore revenue and Rs 1,000+ crore EBITDA in 3-4 years (2x growth). The proposed merger of subsidiary companies has received exchange approvals and NCLT clearance is expected in FY27.